Hope for long COVID sufferers: new drug trial targets debilitating fatigue

NCT ID NCT06128967

First seen May 04, 2026 · Last updated May 06, 2026 · Updated 1 time

Summary

This study tested an experimental medication to see if it could reduce fatigue and other symptoms in adults with long COVID. About 400 participants who had persistent symptoms for over 12 weeks after a COVID-19 infection took either the drug or a placebo. The goal was to improve daily functioning and reduce hospitalizations.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CHRONIC FATIGUE SYNDROME are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • CARDRESEARCH - Cardiologia Assistencial e de Pesquisa

    Belo Horizonte, Minas Gerais, 30150240, Brazil

  • City of Brumadinho

    Brumadinho, Minas Gerais, 35.460-000, Brazil

  • City of Ibirité Public Health Authority

    Ibirité, Minas Gerais, Brazil

  • Governador Valadares City Public Health Authority

    Governador Valadares, Minas Gerais, Brazil

  • Sociedade Padrao de Educacao Superior

    Montes Claros, Minas Gerais, Brazil

  • Universidade Federal de Ouro Preto

    Ouro Preto, Minas Gerais, 35400000, Brazil

Conditions

Explore the condition pages connected to this study.